These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Reduction of pro-inflammatory cytokines through hemodiafiltration.
    Author: Kuo HL, Chou CY, Liu YL, Yang YF, Huang CC, Lin HH.
    Journal: Ren Fail; 2008; 30(8):796-800. PubMed ID: 18791954.
    Abstract:
    BACKGROUND: Hemodialysis (HD) prolongs the life of the patients with end stage renal disease (ESRD), but the survival rates are still lower than the general population. More than half of ESRD patients died from cardiovascular disease (CVD). Recent studies have revealed that CVD is a consequence of vascular inflammation, and that there are active inflammatory processes in ESRD patients. Reports have indicated that ESRD patients have fewer CVD events and better survival with hemodiafiltration (HDF), but the reasons for this remain unclear. This study attempts to prove that HDF reduces the CVD-related cytokines. METHODS: Seventeen adult HD outpatients were put on HDF in our hospital from September 2004 to June 2006. We collected plasma samples before and six months after initiation of HDF. The target pro-inflammatory cytokines selected were interleukin-6 (IL-6), interleukin-18 (IL-18), tumor necrosis factor-alpha (TNF-alpha), and C-reactive protein (CRP). RESULTS: After six months of HDF, most of the biochemical parameters did not changed. Plasma IL-18 and TNF-alpha are decreased significantly (p < 0.05) but IL-6 and CRP are not. CONCLUSIONS: IL-18 and INF-alpha decreased significantly after six months of HDF. These cytokines are key factors in atherosclerotic plaque formation and rupture, and a reduction of these inflammatory cytokines in HDF may reduce the CVD incidence and prolong life.
    [Abstract] [Full Text] [Related] [New Search]